343 related articles for article (PubMed ID: 16986129)
1. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.
Yang DH; Lee JJ; Mun YC; Shin HJ; Kim YK; Cho SH; Chung IJ; Seong CM; Kim HJ
Am J Hematol; 2007 Jan; 82(1):1-5. PubMed ID: 16986129
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
3. [Studies of treatment strategy and prognosis on acute myeloid leukemia with chromosome 8 and 21 translocation].
Shi HX; Jiang B; Qiu JY; Lu XJ; Fu JF; Wang DB; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):481-4. PubMed ID: 16383240
[TBL] [Abstract][Full Text] [Related]
4. [Retrospective analysis of treatment outcomes in 70 patients with t(8;21) acute myeloid leukemia].
Numata A; Fujimaki K; Aoshima T; Onizuka M; Hagihara M; Miyazaki K; Fujita H; Sakai R; Machida S; Tanaka E; Nakajima Y; Hattori Y; Tanaka M; Yamazaki E; Shirasugi Y; Inoue Y; Watanabe S; Fujisawa S
Rinsho Ketsueki; 2012 Jul; 53(7):698-704. PubMed ID: 22975772
[TBL] [Abstract][Full Text] [Related]
5. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
[TBL] [Abstract][Full Text] [Related]
6. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
[TBL] [Abstract][Full Text] [Related]
7. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation.
Gorin NC; Labopin M; Frassoni F; Milpied N; Attal M; Blaise D; Meloni G; Iori AP; Michallet M; Willemze R; Deconninck E; Harousseau JL; Polge E; Rocha V
J Clin Oncol; 2008 Jul; 26(19):3183-8. PubMed ID: 18506024
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
[TBL] [Abstract][Full Text] [Related]
9. Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution's experience.
Lee KW; Choi IS; Roh EY; Kim DY; Yun T; Lee DS; Yoon SS; Park S; Kim BK; Kim NK
Ann Hematol; 2004 Apr; 83(4):218-24. PubMed ID: 14628154
[TBL] [Abstract][Full Text] [Related]
10. FLT3-internal tandem duplication in a pediatric patient with t(8;21) acute myeloid leukemia.
Kawamura M; Kaku H; Ito T; Funata N; Taki T; Shimada A; Hayashi Y
Cancer Genet Cytogenet; 2010 Dec; 203(2):292-6. PubMed ID: 21156247
[TBL] [Abstract][Full Text] [Related]
11. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
Raspadori D; Damiani D; Michieli M; Stocchi R; Gentili S; Gozzetti A; Masolini P; Michelutti A; Geromin A; Fanin R; Lauria F
Haematologica; 2002 Nov; 87(11):1135-40. PubMed ID: 12414342
[TBL] [Abstract][Full Text] [Related]
12. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
13. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
[TBL] [Abstract][Full Text] [Related]
15. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
16. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
17. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of CD56 antigen expression in acute myeloid leukemia.
Di Bona E; Sartori R; Zambello R; Guercini N; Madeo D; Rodeghiero F
Haematologica; 2002 Mar; 87(3):250-6. PubMed ID: 11869936
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome.
Chang H; Brandwein J; Yi QL; Chun K; Patterson B; Brien B
Leuk Res; 2004 Oct; 28(10):1007-11. PubMed ID: 15289011
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]